Associated Genetic Biomarkers
CDKN2C Loss is present in 0.19% of AACR GENIE cases, with conventional glioblastoma multiforme, glioblastoma, and gastrointestinal stromal tumor having the greatest prevalence .
CDKN2C Loss serves as an inclusion eligibility criterion in 6 clinical trials, of which 5 are open and 1 is closed. Of the trials that contain CDKN2C Loss as an inclusion criterion, 3 are early phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open).
Trials with CDKN2C Loss in the inclusion eligibility criteria most commonly target glioblastoma, malignant glioma, and multiple myeloma .
Abemaciclib, ly3214996, dexamethasone, everolimus, and ixazomib are the most frequent therapies in trials with CDKN2C Loss as an inclusion criteria .
Significance of CDKN2C Loss in Diseases
Malignant Glioma +
CDKN2C is altered in 2.46% of malignant glioma patients with CDKN2C Loss present in 2.16% of all malignant glioma patients .
CDKN2C Loss is an inclusion criterion in 3 clinical trials for malignant glioma, of which 3 are open and 0 are closed. Of the trials that contain CDKN2C Loss and malignant glioma as inclusion criteria, 3 are early phase 1 (3 open) .
CDKN2C is altered in 2.91% of glioblastoma patients with CDKN2C Loss present in 2.61% of all glioblastoma patients .
CDKN2C Loss is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2C Loss and glioblastoma as inclusion criteria, 2 are phase 2 (1 open) .
CDKN2C Loss is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2C Loss and meningioma as inclusion criteria, 1 is early phase 1 (1 open) .
Multiple Myeloma +
CDKN2C Loss is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2C Loss and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.